Trials / Terminated
TerminatedNCT01073644
Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 3 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose is to monitor the safety and tolerability and effectiveness of sunitinib malate in the treatment of patients with metastatic renal cell carcinoma and gastrointestinal stromal tumor among filipino patients in usual clinical practice setting.
Detailed description
Open label
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sunitinib malate | sunitinib 50 mg, 4 weeks on, 2 weeks off |
Timeline
- Start date
- 2010-02-01
- Primary completion
- 2010-04-01
- Completion
- 2010-04-01
- First posted
- 2010-02-23
- Last updated
- 2013-07-04
Locations
2 sites across 1 country: Philippines
Source: ClinicalTrials.gov record NCT01073644. Inclusion in this directory is not an endorsement.